The researchers found that the hazard ratio (HR) was 0.67 for the primary CV outcome associated with GLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RA (13,666 initiators) versus DPP-4i (17,084 initiators), corresponding to an incidence rate difference (IRD) of −21.6 per 1,000 person-years. For the primary hepatic outcome, the HR was 0.47 and IRD was −2.1. The CV benefits were similar for SGLT-2i (11,108 initiators) versus DPP-4i (16,979 initiators), with a HR of 0.82 for the primary CV outcome and IRD of −11.0. For the primary hepatic outcome, the HR and IRD were not significant. Compared with DPP-4i, severe adverse events did not occur more often with GLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RAGLP-1 RA or SGLT-2i.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.